MAP2 and schizophrenia: The following are the limitations of the current study: (1) small iPS sample sizes; (2) iPS samples were not matched between cases and controls in terms of ethnicity and gender; (3) as no histopathological examinations were performed, it would be difficult to completely exclude the possible contribution of ‘gliosis' to elevated GFAP expression in schizophrenia brains; and (4) the precise mechanisms for the upregulation of GFAP and downregulation of MAP2 in the postmortem brain samples from schizophrenia remain elusive.